Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance) von Abou-Alfa, Ghassan K., Niedzwieski, Donna, Knox, Jennifer J., Kaubisch, Andreas, Posey, James, Tan, Benjamin R., Kavan, Petr, Goel, Rakesh, Lammers, Philip Edward, Bekaii-Saab, Tanios S., Tam, Vincent Channing, Rajdev, Lakshmi, Kelley, Robin Kate, Siegel, Abby B., Balletti, Jennifer, Harding, James J., Schwartz, Lawrence HOWARD, Goldberg, Richard M., Bertagnolli, Monica M., Venook, Alan P.

Volltext

Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance) von Abou-Alfa, Ghassan K., Niedzwieski, Donna, Knox, Jennifer J., Kaubisch, Andreas, Posey, James, Tan, Benjamin R., Kavan, Petr, Goel, Rakesh, Murray, John J., Bekaii-Saab, Tanios S., Tam, Vincent Channing, Rajdev, Lakshmi, Kelley, Robin Kate, Siegel, Abby, Balletti, Jennifer, Harding, James J., Schwartz, Lawrence HOWARD, Goldberg, Richard M., Bertagnolli, Monica M., Venook, Alan P.

Volltext